Applying Data Visualization Tools to Advance Cell and Gene Therapy Research

Protein concentration is an obligatory critical quality attribute that is necessary to determine total protein content in biopharmaceutical formulations.

Biologic drugs have dominated the biopharmaceutical market in recent years and show no signs of slowing. While there is no shortage of therapeutic targets for drug developers designing monoclonal antibodies (mAB), validating those targets for clinical efficacy in various disease models is growing increasingly difficult. Since IL-11 was recently identified as an essential cytokine for inflammation and fibrosis, Enleofen and Aldevron developed monoclonal anti-IL-11 and anti-IL11RA antibodies for the treatment of non-alcoholic steatohepatitis (NASH) and other conditions.

The therapeutic antibody market has reached a fever pitch of enthusiasm, in no small part due to successes of recent drug approvals for a host of disorders such as psoriasis, multiple sclerosis, C. difficile infections, and cancer.

During this educational webinar, Dr. Timothy A. Hacker discusses strategies and experimental design of long-term, chronic cardiovascular research in rodents. Specifically, he reviews the use of implantable telemetry, imaging and complimentary technologies for cardiovascular research, highlighting when to adopt one technology versus another and the advantages and limitations of each. He shares best-practices related to data acquisition and analysis, data interpretation and how to prepare data in support of your research hypothesis.